• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

    5/12/25 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIR alert in real time by email

    Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada.

    A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

    About Vir Biotechnology

    Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250512919764/en/

    Media

    Corporate Communications, Vir Biotechnology

    [email protected]

    Investors

    Richard Lepke

    Senior Director, Investor Relations

    [email protected]

    Get the next $VIR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIR

    DatePrice TargetRatingAnalyst
    1/29/2024$23.00 → $9.00Overweight → Neutral
    JP Morgan
    9/8/2023$23.00 → $14.00Buy → Neutral
    BofA Securities
    3/6/2023$35.00 → $34.00Neutral → Overweight
    JP Morgan
    2/21/2023$41.00 → $53.00Neutral → Buy
    Goldman
    1/27/2023$18.00 → $30.00Underweight → Equal-Weight
    Morgan Stanley
    9/14/2022$40.00Outperform
    SVB Leerink
    9/9/2022$15.00Underweight
    Morgan Stanley
    3/3/2022$36.00 → $28.00Underperform → Neutral
    Baird
    More analyst ratings